Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTTx peptide candidate (asthma)
- Development stage
- Preclinical
- Lead developer
- On Target Therapeutics
- Modality
- Peptides
01
Overview
OTTx peptide candidate (asthma) is a preclinical-stage therapeutic being developed by On Target Therapeutics for the treatment of allergic asthma. The drug is a stable, long-acting peptide designed to modulate a specific, though currently undisclosed, G protein-coupled receptor (GPCR). On Target Therapeutics utilizes a proprietary platform to engineer peptides with improved metabolic stability and extended duration of action, aiming to overcome the traditional pharmacokinetic limitations of peptide-based GPCR modulators. The company is currently seeking partners for the further development of this candidate into clinical trials.
Beyond the preview
Go deeper on OTTx peptide candidate (asthma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTTx peptide candidate (asthma).